Suven Pharmaceuticals Ltd announces today that the US Food and Drug Administration (USFDA) completed a pre-approval inspection at Casper Pharma Private Limited (Casper Pharma) formulations manufacturing facility situated at GMR Hyderabad SEZ, a wholly owned subsidiary of Suven Pharmaceuticals Limited Hyderabad, India.
The inspection was conducted from July 25th through Jul 29th, 2022. The audit is part of the agency's inspection for three product applications filed and slated to be manufactured at this site.
We are glad to have completed the audit successfully with Zero observations and at the end of the inspection no form 483 was issued by USFDA which signifies compliance and conformance to applicable cGMP regulations says Venkat Jasti, Managing Director of Suven Pharmaceuticals Limited.
Shares of Suven Pharmaceuticals Limited was last trading in BSE at Rs. 481.15 as compared to the previous close of Rs. 470.75. The total number of shares traded during the day was 15433 in over 1166 trades.
The stock hit an intraday high of Rs. 488.00 and intraday low of 465.70. The net turnover during the day was Rs. 7301140.00.